🇺🇸 FDA
Patent

US 8497393

Process to prepare treprostinil, the active ingredient in Remodulin®

granted A61KA61K31/192A61P

Quick answer

US patent 8497393 (Process to prepare treprostinil, the active ingredient in Remodulin®) held by United Therapeutics Corporation expires Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Jul 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/192, A61P, A61P1/00, A61P1/14